posted on 2024-01-13, 18:06authored byXiao Li, Han-Shen Tae, Shen Chen, Arsalan Yousuf, Linhong Huang, Jinghui Zhang, Tao Jiang, David J. Adams, Rilei Yu
Pain severely affects the physical and mental health
of patients.
The need to develop nonopioid analgesic drugs to meet medical demands
is urgent. In this study, we designed a truncated analogue of αO-conotoxin,
named GeX-2, based on disulfide-bond deletion and sequence truncation.
GeX-2 retained the potency of its parent peptide at the human α9α10
nAChR and exhibited potent inhibitory activity at CaV2.2
channels via activation of the GABAB receptor (GABABR). Importantly, GeX-2 significantly alleviated pain in the
rat model of chronic constriction injury. The dual inhibition of GeX-2
at both α9α10 nAChRs and CaV2.2 channels is
speculated to synergistically mediate the potent analgesic effects.
Results from site-directed mutagenesis assay and computational modeling
suggest that GeX-2 preferentially interacts with the α10(+)α10(−)
binding site of α9α10 nAChR and favorably binds to the
top region of the GABABR2 subunit. The study offers vital
insights into the molecular action mechanism of GeX-2, demonstrating
its potential as a novel nonopioid analgesic.